UNC1999, an EZH2 specific inhibitor, was successful in all three of these model systems, not only reducing aberrant K27 methyl marks that characterize PDAC cells, but also slowing proliferation rates of the cancer cells [56]. This evidence concerns the gene EZH2 and cancer.